from The American Heritage® Dictionary of the English Language, 4th Edition
- n. A cell that is produced in the laboratory from the fusion of an antibody-producing lymphocyte and a nonantibody-producing cancer cell, usually a myeloma or lymphoma. It proliferates and produces a continuous supply of a specific monoclonal antibody.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. A hybrid cell engineered from a lymphocyte and a tumour cell; used to generate monoclonal antibodies
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. a hybrid cell resulting from the fusion of a lymphocyte and a tumor cell; used to culture a specific monoclonal antibody
Sorry, no etymologies found.
Standard methods were available for selectively growing cells with functional HPRT enzymes and had already been used for several years for selection of mutants, hybridoma cells in monoclonal antibody production etc.
The principle features of the hybridoma technology is as follows (Figure 2).
The hybridoma cells can be stored in tissue banks and the very same monoclonal antibody can be used all over the world with a guarantee for eternal supply.
By special arrangements it is possible to achieve a multiplication of hybridoma cells but not of isolated myeloma cells.
The discovery and development of principles for production of the so-called monoclonal antibodies by the hybridoma technique by Georges Köhler and César
The hybridoma technique for the production of monoclonal antibodies represents one of the most important methodological advances in biomedicine during the 1970s.
Köhler and Milstein called these hybrid cells hybridomas, and as all cells in a given hybridoma come from one single hybrid cell, the antibodies made are monoclonal.
Besides gene technology, which has already been honoured by several Nobel Prizes, the hybridoma technique represents the most important methodological advance within the field of biomedicine during the 1970s.
The product of this fusion is referred to as a hybridoma.
César Milstein in 1975 introduced the so-called hybridoma technology for production of monclonal antibodies.